Long-acting injectable antipsychotics and global functioning in north western italian public health service - 08/07/17
pages | 2 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Résumé |
Introduction |
Long-acting injectable antipsychotics (LAI-APs) should be the first choice therapy in the treatment of schizophrenia, however their use in outpatient's psychiatric services remains limited.
Objective |
Observational study in schizophrenic patients of the northwestern public health service.
Aim |
To assess demographic and psychopathological features in patients treated with LAI haloperidol (H-LAI) and second-generation LAI antipsychotics (SG-LAI).
Methods |
We recruited 105 schizophrenic patients upon LAI-APs treatment, and we assessed socio-demographic data, medical comorbidity, substances use, time from admission, treatment length, and per os augmentation therapies. All participants were assessed for global functioning and severity of illness by CGI-SCH and PSP, respectively.
Results |
Of all patients, 52% were treated by H-LAI, 48% by SG-LAI. No statistical differences (P>0.05) were found between the 2 groups for age, gender, other demographic variables, substances use, somatic comorbidities. Both groups were homogeneous for severity of illness (CGI-SCH score=4.20 in H-LAI vs. 4.38 in SG-LAI) and global functioning (PSP score=49.1 in H-LAI vs. 54.4 in SG-LAI). Compared with the H-LAI group, SG-LAI-treated patients were characterized by shorter time from admission (>10yrs) and treatment length (>1yr), and less frequent anticholinergic drug co-prescription. We counted only 6 LAI-APs treatments started in the last year.
Conclusions |
Despite of the literature support, LAI-APs treatment for schizophrenia is still limited in our service. Our data suggest that SG-LAI-APs are used as first choice of LAI-APs treatment, although maintained for short time, while H-LAI are reserved to long-standing patients and are burdened by side effects needing anticholinergic treatment.
Le texte complet de cet article est disponible en PDF.Plan
Vol 41 - N° S
P. S605-S606 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?